P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000936332.73280.e0 |
| _version_ | 1797283776116555776 |
|---|---|
| author | M. Hanna J. Chorazy I. Iheanacho B. Gorsh P.F. Wang P. Paka S. Perera |
| author_facet | M. Hanna J. Chorazy I. Iheanacho B. Gorsh P.F. Wang P. Paka S. Perera |
| author_sort | M. Hanna |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:36:44Z |
| format | Article |
| id | doaj.art-1fe95e01096a420fb3ea14b2cb0cbaf8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:36:44Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1fe95e01096a420fb3ea14b2cb0cbaf82024-03-02T16:40:25ZengWileyHemaSphere2572-92412023-05-017S2383910.1097/01.HS9.0000936332.73280.e0202305002-00070P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEWM. Hanna0J. Chorazy1I. Iheanacho2B. Gorsh3P.F. Wang4P. Paka5S. Perera61 GSK, Collegeville, PA, USA2 Evidera, Evidera, London2 Evidera, Evidera, London1 GSK, Collegeville, PA, USA1 GSK, Collegeville, PA, USA3 GSK, Philadelphia, PA, USA4 GSK, London, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000936332.73280.e0 |
| spellingShingle | M. Hanna J. Chorazy I. Iheanacho B. Gorsh P.F. Wang P. Paka S. Perera P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW HemaSphere |
| title | P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW |
| title_full | P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW |
| title_fullStr | P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW |
| title_full_unstemmed | P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW |
| title_short | P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW |
| title_sort | p51 efficacy and safety of third line or later treatments including the cd38 monoclonal antibody class in patients with relapsed refractory multiple myeloma a systematic literature review |
| url | http://journals.lww.com/10.1097/01.HS9.0000936332.73280.e0 |
| work_keys_str_mv | AT mhanna p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview AT jchorazy p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview AT iiheanacho p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview AT bgorsh p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview AT pfwang p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview AT ppaka p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview AT sperera p51efficacyandsafetyofthirdlineorlatertreatmentsincludingthecd38monoclonalantibodyclassinpatientswithrelapsedrefractorymultiplemyelomaasystematicliteraturereview |